Serotonin transporter clustering in blood lymphocytes predicts the outcome on anhedonia scores in naïve depressive patients treated with antidepressant medication

Annals of General Psychiatry

Tania Rivera-Baltanas³  Roberto Carlos Agis-Balboa³  Raquel Romay-Tallon²  Lisa E. Kalynchuk¹  Jose Manuel Olivares³  Hector J. Caruncho² 

[1] Division of Neurology, Department of Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

[2] Division of Pharmacy, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Saskatoon S7N 5E5, SK, Canada

[3] Instituto de Investigaciones Biomédicas de Vigo (IBIV), Rebullon Psychiatric Hospital, Vigo, Galicia, Spain

关键词: Protein clustering;    Serotonin;    Psychiatric scales;    Depression symptoms;    Biomarker;   

Others  :  1235040
DOI  :  10.1186/s12991-015-0085-8

 received in 2015-06-16, accepted in 2015-12-03,  发布年份 2015

【 摘 要 】

Background

We have shown that serotonin transporter (SERT) clustering in blood lymphocytes is altered in major depression and correlates with pharmacological therapeutic responses measured with the Hamilton scale. In the present report, we extend these results to the self-assessment anhedonia scale, as anhedonia is a cardinal symptom of major depression that is difficult to treat with first-line antidepressants.

Methods

We collected blood samples from 38 untreated depression patients at the time of enrolment and 8 weeks after pharmacological treatment. We used the self-assessment anhedonia scale to evaluate anhedonia symptoms before and after treatment. We also used quantitative immunocytochemistry to measure SERT clusters in blood lymphocytes.

Results

Evaluation of the distribution of SERT clusters size in the plasma membrane of lymphocytes identified two subpopulations of naive depression patients: Depression I (D-I) and Depression II (D-II). While naïve D-I and D-II patients initially showed similar anhedonia scores, D-II patients showed a good response in anhedonia symptoms after 8 weeks of psychopharmacological treatment, whereas D-I patients failed to show any improvement. Psychopharmacological treatment also induced an increase in the number of SERT clusters in lymphocytes in the D-II group, and this increase correlated with the improvement in anhedonia symptoms.

Conclusions

SERT clustering in peripheral lymphocytes can be used to identify patient response to antidepressant therapy as ascertained by anhedonia scores.

【 授权许可】

   
2015 Rivera-Baltanas et al.

【 图 表 】

Fig.1.

Fig.2.

【 参考文献 】

• [1]American Psychiatric Association. Depressive disorders. In: Diagnostic and statistical manual of mental disorders, 5th edn. Washington, DC: American Psychiatric Publishing; 2013. pp. 155–88.
• [2]Buckner JD, Joiner TE Jr, Pettit JW, et al.: Implications of the DSM’s emphasis on sadness and anhedonia in major depressive disorder. Psychiatry Res 2008, 159:25-30.
• [3]http://www.who.int/mental_health/prevention/suicide/suicideprevent/en/.
• [4]Belmaker RH, Agam GN: Major depressive disorder. N Engl J Med 2008, 358:55-68.
• [5]Rush AJ, Trivedi MH, Wisniewski SR, et al.: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
• [6]Wijeratne C, Sachdev P: Treatment-resistant depression: critique of current approaches. Aust N Z J Psychiatry 2008, 42:751-762.
• [7]Cipriani A, Geddes JR, Furukawa TA, et al.: Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. Can J Psychiatry 2007, 52:553-562.
• [8]Cipriani A, Furukawa TA, Salanti G, et al.: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373:746-758.
• [9]Barbui C, Furukawa TA, Cipriani A: Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2008, 178:296-305.
• [10]Rivera-Baltanas T, Caruncho HJ: Biomarkers of depression. Rev Neurol 2010, 50:470-476.
• [11]Rivera-Baltanas T, Olivares JM, Calado-Otero M, et al.: Serotonin transporter clustering in blood lymphocytes as a putative biomarker of therapeutic efficacy in major depressive disorder. J Affect Disord 2012, 137:46-55.
• [12]Rivera-Baltanas T, Olivares JM, Martinez-Villamarin JR, et al.: Serotonin 2A receptor clustering in peripheral lymphocytes is altered in major depression and may be a biomarker of therapeutic efficacy. J Affect Disord 2014, 163:47-55.
• [13]Hamilton M: A rating scale for depression. JNNP 1960, 23:56-62.
• [14]Berrios GE, Olivares JM: The anhedonias: a conceptual history. Hist Psychiatry 1995, 6:453-470.
• [15]Olivares JM, Berrios GE: The anhedonias: clinical and neurobiological aspects. Int J Psychiatr Clin Pract 1998, 2:157-171.
• [16]Shelton RC, Tomarken AJ: Can recovery form depression be achieved? Psychiatry Serv 2001, 52:1469-1478.
• [17]Nutt K, Demyttenaere Z, Janka T, et al.: The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2010, 25:328-333.
• [18]McCabe C, Cowen PJ, Harmer CJ: Neural representation of reward in recovered depressed patients. Psychopharmacol 2009, 205:667-677.
• [19]Spijker J, Bijl RV, de Graaf R, et al.: Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand 2001, 103:122-130.
• [20]Pizzagalli DA: Depression, stress, and anhedonia: towards a synthesis and integrated model. Annu Rev Clin Psychol 2014, 10:393-423.
• [21]Chapman LJ, Chapman JP, Raulin ML: Scales for physical and social anhedonia. J Abnorm Psychol 1976, 85:374-382.
• [22]Olivares JM, Berrios GE, Bousono M: The self-assessment anhedonia scale. Neurol Psychiatr Brain Res 2005, 12:121-134.
• [23]Rivera-Baltanas T, Romay-Tallon R, Dopeso-Reyes IG, et al. Serotonin transporter clustering in blood lymphocytes of reeler mice. Cardiovasc Psychiatry Neurol. 2010; 396282.
• [24]Snaith RP, Hamilton M, Morley S, et al.: A scale for the assessment of hedonic tone the Snatih-Hamilton pleasure scale. Br J Psychiatry 1995, 167:99-103.
• [25]Franken IHA, Rassin E, Muris P: The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton pleasure scale (SHAPS). J Affect Disord 2007, 99:83-89.
• [26]Ho N, Sommers M: Anhedonia: a concept analysis. Arch Psychiatr Nurs 2013, 27:121-129.
• [27]Horan WP, Brown SA, Blanchard JJ: Social anhedonia and schizotypy: the contribution of individual differences and affective traits, stress, and coping. Psychiatry Res 2007, 149:147-156.
• [28]Pelizza L, Ferrari A: Anhedonia in schizophrenia and major depression: state or trait? Ann Gen Psychiatry 2009, 8:22. BioMed Central Full Text
• [29]Nakonezny PA, Carmody TJ, Morris DW, et al.: Psychometric evaluation of the Snaith-Hamilton pleasure scale in adult outpatients with major depressive disorder. Int Clin Psychoparmacol 2010, 25:328-333.
• [30]Cook M, Simukonda F: Anhedonia and schizophrenia. Br J Psychiatry 1981, 139:523-525.
• [31]Anisman H, Kokkinidis L, Merali Z: Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav Immun 2002, 16:544-556.
• [32]Tomarken AJ, Dichter GS, Freid C, et al.: Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord 2004, 78:235-241.
• [33]Martinotti G, Sepede G, Gambi F, et al.: Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder. J Clin Psychopharmacol 2012, 32(4):487-491.
• [34]Di Giannantonio M, Martinotti G: Anhedonia and major depression: the role of agomelatine. Eur Neuropsychopharmacol 2012, 22:S505-S510.